Navigation Links
Inhibiting key enzymes kills difficult tumor cells in mice
Date:8/15/2011

Tumors that do not respond to chemotherapy are the target of a cancer therapy that prevents the function of two enzymes in mouse tumor cells, according to Pennsylvania medical researchers.

"We've known for well over a decade that when tumors become hypoxic they become resistant to chemotherapy and radiotherapy," said Wafik S. El-Deiry, M.D. Ph.D., American Cancer Society Research Professor, Rose Dunlap Professor and chief of hematology/oncology, Penn State College of Medicine. "This is a huge problem in the treatment of patients with cancer. As tumors progress, they have regions that are not well perfused with blood vessels and tumors become hypoxic."

A hypoxic tumor lacks oxygen because there are not enough blood vessels within the tumor to allow red blood cells to transport oxygen throughout the tumor.

El-Deiry and his team report in a recent issue of Cancer Research that the drug sangivamycin-like molecule 3 (SLM3) helps keep tumor cells from multiplying in lab mice.

Treating a tumor with SLM3 inhibits two kinase, or enzymes: GSK-3, which regulates cell growth and cell death, and CDK1, which regulates cell division and blood vessel growth. Tumor cells treated with SLM3 become more sensitive to chemotherapy and die, according to El-Deiry and his colleagues.

"If you just inhibit GSK-3, that may not be enough and not necessarily desirable," said El-Deiry, who is also the associate director for translational research, Cancer Institute. "But there's something fortuitous about the dual targeting of these two kinases, (GSK-3 and CDK-1), with respect to cancer therapy. If you inhibit these two kinases, the dual inhibition works together to kill hypoxic tumor cells.

"While pure inhibition of GSK-3 can promote cell proliferation, the combination of GSK-3 and CDK-1 inhibition not only inhibits cell proliferation but also promotes cell death," El-Deiry added.

To find SLM3, the researchers screened a chemical library looking for molecules that induce apoptosis -- cell death -- in hypoxic tumor cells. SLM3 does that, and the researchers found eight molecules whose structures were similar.

SLM3 was the version that induced the most cell death in concert with TRAIL, a naturally occurring molecule in the body that tells a cell it is time to die. TRAIL sets a process in motion that targets and shuts down tumor cells and keeps them from spreading.

SLM3, a nucleoside analog, helps keep tumor cells from multiplying by stopping cells before they duplicate their DNA. Nucleosides are the building blocks of nucleic acids and molecules like ATP -- the energy source for the body. A nucleoside analog competes with ATP and inhibits kinases, like GSK-3 and CDK1.

GSK-3 helps regulate cell growth and cell death. CDK1 decreases the tumor's ability to divide and generate more blood vessels. SLM3 inhibits both these kinases.

"The bottom line is the molecules actually work to shrink tumors when these molecules are combined with chemo or TRAIL therapy," El-Deiry said. "We think that these are important observations that need to be tested further in the clinic."


'/>"/>

Contact: Victoria M. Indivero
vmi1@psu.edu
814-865-9481
Penn State
Source:Eurekalert

Related medicine news :

1. Inhibiting fatty acids in immune cells decreases atherosclerosis risk
2. Inhibiting prostate cancer without disturbing regular body processes
3. Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders
4. New evidence that smokeless tobacco damages DNA and key enzymes
5. Heart Enzymes May Predict Outcome After Bypass Surgery
6. New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman
7. Cognitive Skills May Shrink With Tamoxifen
8. Stethoscope App gives iPhone New Clinical Skills
9. Paper Kills 2.0 Book by Center for Health Transformation Features Chapter by StatCom
10. PeopleStreme Collaborates with SkillSoft for Learning Management Content
11. New agent chokes off energy supply, kills cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... , ... February 26, 2017 , ... ... for entries to the 7th Edition of International Social Design Awards. , ... Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects and ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a new ... B2B Sellers will now only pay for B.A.N.T. quality sales leads based on the ... said, “Given the new reality that B2B buyers are controlling the sales process via ...
(Date:2/26/2017)... ... 26, 2017 , ... Occupational pesticide exposure is linked to ... mutation, according to a study released today at the 1st Pan American Parkinson’s ... between pesticides and incidence of sporadic PD through occupational exposure. This latest study, ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition ... has initiated a second print-run of its lavish luxury travel coffee table book. ... weighs in at more than six kilos, retails at EUR 1,000 per copy and ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age ... Oxford University predict that 47 percent of all jobs in the United States may ... and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017   Royal Philips (NYSE: ... leader in health technology, today announced 510(k) clearance ... to market its ElastQ Imaging capability, further expanding ... systems. ElastQ Imaging enables simultaneous imaging of tissue ... for the diagnosis of various liver conditions. With ...
(Date:2/27/2017)... --  Vitasome ® Labs , Inc. has launched ... new liposome technology. Whereas vitamins lose on average between ... Physician,s Desk Reference , Vitasome , s ® ... and are scientifically formulated to: ... Improve bioavailability with a vastly higher absorption rate ...
(Date:2/27/2017)... , Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... conferences. Raymond James and Associates, 38 ... 6, 2017 in Orlando, FL. ... a.m. ET on March 7, 2017 in Boston, MA. ... March 16, 2017 in Miami, FL. ...
Breaking Medicine Technology: